SCHEMBL23213713

SCHEMBL23213713

CCc1cnc(NC(=O)O)s1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 3/20 0.66
CDK2 P24941 3/20 0.66
CDK5 Q00535 2/20 0.66
FDPS P14324 1/20 0.55
ALDH1A1 P00352 3/20 0.51
TSHR P16473 1/20 0.51
NPC1 O15118 5/20 0.48
RAB9A P51151 5/20 0.48
LMNA P02545 4/20 0.48
TP53 P04637 2/20 0.48
SMN1; SMN2 Q16637 7/20 0.47
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
KDM4E B2RXH2 3/20 0.44
NFKB1 P19838 3/20 0.44
NFKB2 Q00653 3/20 0.44
RELA Q04206 3/20 0.44
MAPT P10636 3/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11224487 0.88 CCNE1 (0.61) CCNE1CDK2CDK5FDPSALDH1A1
SCHEMBL233711 0.87 CDK2 (0.60) CCNE1CDK2CDK5FDPSLMNA
SCHEMBL15825086 0.85 CCNE1 (0.50) CCNE1CDK2CDK5FDPSALDH1A1
SCHEMBL15825211 0.84 CCNE1 (0.49) CCNE1CDK2CDK5ALDH1A1TSHR
SCHEMBL19364715 0.83 MEN1 (0.63) CCNE1CDK2CDK5FDPSTSHR
SCHEMBL11919154 0.82 ALDH1A1 (0.70) CCNE1CDK2CDK5FDPSALDH1A1
SCHEMBL11225514 0.82 ALDH1A1 (0.58) CCNE1CDK2CDK5FDPSALDH1A1
SCHEMBL21807900 0.82 CCNE1 (0.48) CCNE1CDK2CDK5FDPSALDH1A1
SCHEMBL5653949 0.82 CCNE1 (0.55) CCNE1CDK2CDK5FDPSALDH1A1
SCHEMBL14476225 0.82 SMN1; SMN2 (0.57) CCNE1CDK2CDK5FDPSALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 CCNE1 570/4885CDK2 494/4885CDK5 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.